Clinical course of psoriasis patients that discontinued biologics during the COVID-19 pandemic

dc.authoridSarikaya Solak, Sezgi/0000-0002-8572-8249
dc.authoridTopaloglu Demir, Filiz/0000-0002-2049-1316
dc.authorwosidSarikaya Solak, Sezgi/A-4789-2016
dc.contributor.authorDemir, Filiz Topaloğlu
dc.contributor.authorEkinci, Algün Polat
dc.contributor.authorAytekin, Sema
dc.contributor.authorTopkarçı, Zeynep
dc.contributor.authorKayıran, Melek Aslan
dc.contributor.authorAkbulut, Tuğba Özkök
dc.contributor.authorTopal, İlteriş Oğuz
dc.date.accessioned2023-05-06T17:22:13Z
dc.date.available2023-05-06T17:22:13Z
dc.date.issued2023
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Deri ve Zührevi Hastalıkları Ana Bilim Dalı
dc.description.abstractBackgroundSince psoriasis is a chronic disease, it is not recommended to discontinue the treatment agents used. However, in real life, the treatment of psoriasis patients may be interrupted for various reasons. During the pandemic period, the treatment of many patients was also interrupted. ObjectivesTo evaluate relapse and clinical worsening in psoriasis patients whose biological therapy was interrupted during the pandemic and reveal associated factors. MethodsThe study included patients aged >= 18 years, who were followed up with moderate and severe chronic psoriasis controlled by the last biological agent [Psoriasis Area Severity Index (PASI) 75 response achieved] but had to discontinue their treatment during the pandemic. The patients' demographic and clinical characteristics, clinical course after the discontinuation of these agents, presence of clinical worsening, and relapse were evaluated. Risk factors were analyzed with the logistic regression analysis. ResultsThe study included 169 patients, with a mean age of 47.3 +/- 14.5 (18-87) years. The mean biologics-free time was 18.2 +/- 12.3 (2-56) weeks. Clinical worsening was detected in 41.4% and relapse in 48.5% of the patients. The significant risk factors for clinical worsening and relapse in both univariate and multivariate analyses were alcohol use during the biologics-free period, total time off biologics, and the presence of an additional triggering factor. The use of secukinumab and ustekinumab was found to be a protective factor against clinical worsening in multivariate analyses. ConclusionAs the biologics-free period is prolonged, the likelihood of clinical worsening and relapse increases, therefore, we do not recommend discontinuing biological agents.
dc.identifier.doi10.1111/jocd.15638
dc.identifier.endpage731
dc.identifier.issn1473-2130
dc.identifier.issn1473-2165
dc.identifier.issue3en_US
dc.identifier.pmid36630728
dc.identifier.scopus2-s2.0-85146251492
dc.identifier.scopusqualityQ2
dc.identifier.startpage722
dc.identifier.urihttps://doi.org/10.1111/jocd.15638
dc.identifier.urihttps://hdl.handle.net/20.500.11776/12120
dc.identifier.volume22
dc.identifier.wosWOS:000912688300001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorAytekin, Sema
dc.language.isoen
dc.publisherWiley
dc.relation.ispartofJournal Of Cosmetic Dermatology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectmedical therapy
dc.subjectpsoriasis
dc.subjecttreatment
dc.subjectRegistry
dc.subjectTherapy
dc.subjectSafety
dc.titleClinical course of psoriasis patients that discontinued biologics during the COVID-19 pandemic
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
12120.pdf
Boyut:
805.54 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text